Related Experiment Videos
A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle
R Morishita1, G H Gibbons, M Horiuchi
1Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine, CA 94305-5246, USA.
Abstract:
The application of DNA technology to regulate the transcription of disease-related genes in vivo has important therapeutic potentials. The transcription factor E2F plays a pivotal role in the coordinated transactivation of cell cycle-regulatory genes such as c-myc, cdc2, and the gene encoding proliferating-cell nuclear antigen (PCNA) that are involved in lesion formation after vascular injury. We hypothesized that double-stranded DNA with high affinity for E2F may be introduced in vivo as a decoy to bind E2F and block the activation of genes mediating cell cycle progression and intimal hyperplasia after vascular injury. Gel mobility-shift assays showed complete competition for E2F binding protein by the E2F decoy. Transfection with E2F decoy inhibited expression of c-myc, cdc2, and the PCNA gene as well as vascular smooth muscle cell proliferation both in vitro and in the in vivo model of rat carotid injury. Furthermore, 2 weeks after in vivo transfection, neointimal formation was significantly prevented by the E2F decoy, and this inhibition continued up to 8 weeks after a single transfection in a dose-dependent manner. Transfer of an E2F decoy can therefore modulate gene expression and inhibit smooth muscle proliferation and vascular lesion formation in vivo.
Insights
Introducing an E2F decoy DNA effectively blocks the activation of cell cycle genes. This therapeutic approach significantly inhibits smooth muscle cell proliferation and prevents vascular lesion formation in vivo.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Gene Therapy
Background:
- The transcription factor E2F regulates cell cycle genes crucial for vascular injury response.
- Uncontrolled smooth muscle cell proliferation contributes to intimal hyperplasia and vascular lesion formation.
- Targeting E2F offers a potential therapeutic strategy for vascular diseases.
Purpose of the Study:
- To investigate the efficacy of an E2F decoy DNA in inhibiting gene transcription and vascular smooth muscle cell proliferation.
- To evaluate the therapeutic potential of E2F decoy in preventing neointimal formation after vascular injury in vivo.
Main Methods:
- Gel mobility-shift assays were used to confirm E2F decoy binding affinity.
- In vitro and in vivo transfection models (rat carotid artery injury) were employed.
- Expression levels of c-myc, cdc2, and PCNA were assessed post-transfection.
Main Results:
- E2F decoy demonstrated high affinity for E2F, effectively blocking its binding.
- Transfection with E2F decoy significantly inhibited c-myc, cdc2, and PCNA gene expression.
- Inhibition of vascular smooth muscle cell proliferation and a dose-dependent reduction in neointimal formation were observed in vivo.
Conclusions:
- E2F decoy DNA serves as an effective tool to modulate gene expression in vivo.
- This approach successfully inhibits smooth muscle cell proliferation and prevents vascular lesion development.
- E2F decoy gene therapy holds promise for treating vascular proliferative diseases.